Provention Bio Inc., a Lebanon-based clinical-stage biopharmaceutical company, said Tuesday it has named a new chief medical and chief operating officer to help it build its pipeline of therapeutics and solutions for chronic autoimmune and inflammatory diseases.
Dr. Eleanor “Leni” Ramos has more than 20 years of biopharma experience, the company said in a news release, and will work alongside company co-founders Ashleigh Palmer and Dr. Francisco Leon in her new role.
“Having seen and treated patients who have suffered the irreversible sequelae of chronic immune and inflammatory disorders, I’m very excited to be involved in the paradigm-shifting vision of Provention, which seeks to identify and prevent the underlying cause or trigger of these diseases by intervening before the targeted disease begins, reappears or progresses,” Ramos said in a prepared statement. “I welcome the opportunity to join Ashleigh and Francisco and transform this profound vision into a world-class clinical development company.”
Ramos most recently was chief medical officer of Global Blood Therapeutics, a biopharmaceutical company focused on therapies for blood-based and hypoxemic pulmonary disorders. She has also served as CMO for Theraclone Sciences and ZymoGenetics, as well as serving as an executive and director with companies such as Roche Global Development and Bristol-Myers Squibb.
“Adding a biopharmaceutical executive of Leni’s caliber so soon after our founding financing is a tremendous achievement for Provention,” Palmer, the CEO, said in a statement. “Her significant clinical experience and expertise in autoimmunity, inflammation, organ transplant rejection and the treatment of acute and chronic viral infections will help fulfill our vision of pre-empting, slowing and reversing the progression of immune-mediated disease.”